Back to top
more

Ligand Pharmaceuticals (LGND)

(Real Time Quote from BATS)

$110.52 USD

110.52
42,135

-4.93 (-4.27%)

Updated Nov 15, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion

by Zacks Equity Research

Novartis (NVS) obtains FDAs approval for the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) for pediatric brain cancer.

Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78%

by Zacks Equity Research

Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.

How Much Upside is Left in Ligand (LGND)? Wall Street Analysts Think 49.11%

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 49.1% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?

by Zacks Equity Research

Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

by Zacks Equity Research

Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.

Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up

by Zacks Equity Research

Ligand Pharmaceuticals (LGND) announces better-than-expected results in fourth-quarter 2022. Stock is up in the after-market hours in response to the news. Management raises 2023 financial outlook.

Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Merus N.V. (MRUS): Can Its 12.6% Jump Turn into More Strength?

by Zacks Equity Research

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AbbVie (ABBV) Q4 Earnings Beat Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 1.69% and 1.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Ligand (LGND) Stock?

by Zacks Equity Research

Investors need to pay close attention to Ligand (LGND) stock based on the movements in the options market lately.

LGND vs. INCY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

LGND vs. INCY: Which Stock Is the Better Value Option?

Are Investors Undervaluing Ligand Pharmaceuticals (LGND) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LGND or GMAB: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LGND vs. GMAB: Which Stock Is the Better Value Option?

Is BioNTech (BNTX) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Ligand (LGND) Down 3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand (LGND) Beats on Q3 Earnings, Lags Sales, Ups '22 Outlook

by Zacks Equity Research

Ligand (LGND) reports mixed third-quarter 2022 numbers, beating sales estimates but missing out on earnings. Share price rises as management lifts financial guidance for the year.

Ligand Pharmaceuticals (LGND) Misses Q3 Earnings Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -8.89% and 71.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Heska (HSKA) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Heska (HSKA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand Pharmaceuticals (LGND) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Ligand (LGND) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LGND vs. RGEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

LGND vs. RGEN: Which Stock Is the Better Value Option?

Strength Seen in Amgen (AMGN): Can Its 5.7% Jump Turn into More Strength?

by Zacks Equity Research

Amgen (AMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 17.14% and 26.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rimmi Singhi headshot

Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses

by Rimmi Singhi

Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.